Developed via the company’s proprietary Eclipsor platform, BEA-28 functions as a cereblon-recruiting agent. In preclinical testing, the compound demonstrated the ability to shrink tumors in mesothelioma and KRAS-mutant lung cancer models while restoring sensitivity to existing KRAS inhibitors. By eliminating TEAD proteins, the molecule addresses a critical mechanism of tumor growth and immune evasion that conventional inhibitors often fail to suppress.

CEO Per Källblad confirmed that the candidate successfully met all internal benchmarks for pharmacology, chemistry, and pharmacokinetic performance. The development team is now transitioning to final validation steps, including scale-up chemistry and non-regulatory toxicology. Beactica intends to pair the drug with a biomarker-driven patient selection strategy, focusing on clinical combinations with checkpoint inhibitors and KRAS-targeted therapies to treat cancers with high unmet medical needs.